LinkMed: IMED Issued European Patent

STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: The European Patent Office has issued LinkMed’s (STO:LMED) portfolio company IMED AB a patent titled, “Fas peptides and antibodies for modulating apoptosis”. The patent covers IMED’s core technology; the generation of human antibody molecules that binds the human Fas receptor. The issuance of the patent strengthens IMED’s intellectual property position further.